Briefing
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Ongoing EBV DNA-integral randomized phase II/III trial (NRG-HN001): post-chemoradiation plasma EBV DNA is used to assign adjuvant therapy. Enrollment 924. A peer-reviewed primary efficacy results paper was not identified as of 13 Nov 2026.
- Design: Phase 2 / 3 · Active, not recruiting